One-year RRP in regard to the shared epitope and ACPA status
| RRP+ (n) | RRP+ and ACPA+ (n) | RRP− (n) | RRP− and ACPA+ (n) | OR (95% CI) | p Value (χ2) | |
|---|---|---|---|---|---|---|
| Anti-CCP2 | ||||||
| Shared epitope + | 87 | 62 | 205 | 126 | 1.55 (0.88 to 2.80) | NS |
| Shared epitope − | 51 | 25 | 198 | 46 | 3.18 (1.59 to 6.32) | 0.0003 |
| Anti-MCV | ||||||
| Shared epitope + | 87 | 65 | 205 | 132 | 1.63 (0.91 to 3.02) | NS |
| Shared epitope − | 51 | 24 | 198 | 64 | 1.86 (0.94 to 3.64) | 0.0496 |
| AhFibA | ||||||
| Shared epitope + | 87 | 66 | 205 | 132 | 1.74 (0.96 to 3.24) | NS |
| Shared epitope − | 51 | 27 | 198 | 56 | 2.85 (1.44 to 5.63) | 0.0009 |
ACPA, anticitrullinated peptide antibodies; AhFibA, antihuman citrullinated fibrinogen antibodies; anti-CCP2, anticyclic citrullinated peptides generation 2 antibodies; anti-MCV, antimutated citrullinated vimentine antibodies; N, number of patients; NS, not significant; p, results of χ2 test; RRP, patients with rapid radiographic progression.